文献速递血栓与止血

免疫性血小板减少症患者自我注射罗米司亭的安全性与有效性:五项临床试验整合数据库分析

Safety and efficacy of self-administered romiplostim in patients with immune thrombocytopenia: Results of an integrated database of five clinical trials.
PubMed 文献 · Am J Hematol · 2020-03-21

基于五项临床试验的整合分析,评估成人免疫性血小板减少症(ITP)患者自我注射罗米司亭的疗效与安全性。自我注射组621例与医护人员给药组133例相比,达到至少一次血小板反应的比例分别为95.0%和100.0%,中位有反应周百分比分别为94.5%和95.9%,自我注射未对安全性产生不利影响。

要点

  • 自我注射罗米司亭在符合条件的ITP患者中显示有效且耐受性良好。
  • 自我注射组与医护人员给药组血小板反应率及反应持续时间相近。
  • 自我注射未增加治疗中出现的不良事件或出血事件风险。

核心结论

  • 罗米司亭自我注射在符合条件的ITP患者中似乎有效且耐受性良好。

研究设计与样本

  • 对五项临床试验的整合分析,纳入接受每周罗米司亭自我注射或医护人员给药的成人ITP患者。
  • 自我注射组621例,医护人员给药组133例;患者需达到稳定剂量且血小板计数≥50×10^9/L。

主要发现

  • 自我注射组与医护人员给药组分别有95.0%和100.0%的患者达到至少一次血小板反应(定义为每周血小板计数≥50×10^9/L且前4周未使用 rescue 药物)。
  • 有反应周的中位百分比分别为94.5%和95.9%; rescue 药物使用率分别为36.7%和39.8%。
  • 自我注射未对安全性产生不利影响;所有治疗中出现的不良事件(TEAE)和出血TEAE的持续时间调整发生率在自我注射组数值上更低。

关键数值与推荐

  • 血小板反应定义为每周血小板计数≥50×10^9/L且前4周未使用 rescue 药物。
  • 自我注射组中位年龄53岁,医护人员给药组58岁;中位基线血小板计数分别为19.0×10^9/L和20.0×10^9/L。

临床怎么用

  • 符合条件的ITP患者可考虑自我注射罗米司亭,以减少每周就诊需求。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Romiplostim self-administration by patients or caregivers may offer time/cost savings to healthcare professionals (HCPs) and convenience for patients who avoid weekly clinic visits. We performed an integrated analysis of five clinical trials to evaluate the efficacy and safety of romiplostim self-administration. Data were analyzed from adults with immune thrombocytopenia (ITP) who received weekly romiplostim via self-administration or from an HCP. Patients who achieved a stable romiplostim dose for ≥3 weeks (HCP group ≥5 weeks to provide an appropriate index date to enable comparisons with the self-administration group) with platelet counts ≥50 × 109 /L were eligible. In the self-administration (n = 621) vs HCP (n = 133) groups, respectively, median age was 53 vs 58 years, median time since primary ITP diagnosis was 3.7 vs 2.5 years, and median baseline platelet count at ITP diagnosis was 19.0 vs 20.0 × 109 /L. In the self-administration and HCP-dosed groups, median romiplostim treatment duration was 89 vs 52 weeks and median total number of doses was 81 vs 50, respectively. In the self-administration and HCP groups, respectively: 95.0% and 100.0% of patients achieved ≥1 platelet response (defined as weekly platelet count ≥50 × 109 /L without rescue medication in previous 4 weeks); the median percentage of weeks with a response was 94.5% and 95.9%; and rescue medication was used in 36.7% and 39.8% of patients. Self-administration did not adversely affect safety; duration-adjusted rates for all treatment-emergent adverse events (TEAEs) and bleeding TEAEs were numerically lower with self-administration. Romiplostim self-administration appears effective and well tolerated in eligible patients with ITP.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Kuter DJ, Arnold DM, Rodeghiero F, et al. Safety and efficacy of self-administered romiplostim in patients with immune thrombocytopenia: Results of an integrated database of five clinical trials. Am J Hematol. 2020. PMID: 32129511. doi:10.1002/ajh.25776

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。